In March, the companies said their antibody drug, called sotrovimab, was 85 percent effective at reducing virus-related hospitalizations and death in a phase 3 clinical trial.
GlaxoSmithKline and Vir said the drug will be available in the U.S. “in the coming weeks.”
Sotrovimab is the third single antibody drug the FDA has cleared to treat COVID-19, as treatments developed by Eli Lilly and Regeneron have also received emergency use authorizations.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.